Press coverage about Anthera Pharmaceuticals (NASDAQ:ANTH) has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.2112282791525 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

A number of equities research analysts have recently issued reports on the company. Jefferies Group LLC restated a “hold” rating and set a $2.25 price objective on shares of Anthera Pharmaceuticals in a report on Monday, May 15th. ValuEngine cut Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research cut Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Anthera Pharmaceuticals presently has an average rating of “Hold” and an average price target of $10.21.

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) opened at 1.56 on Friday. Anthera Pharmaceuticals has a 52 week low of $1.47 and a 52 week high of $3.55. The company has a 50 day moving average price of $1.66 and a 200 day moving average price of $1.06. The company’s market capitalization is $15.72 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.47) by $0.56. On average, equities research analysts expect that Anthera Pharmaceuticals will post ($5.06) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Insider Buying and Selling by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.